Comparison of Three Transcytotic Pathways for Distribution to Brain Metastases of Breast Cancer

Author:

Khan Imran1ORCID,Gril Brunilde1ORCID,Paranjape Anurag N.1ORCID,Robinson Christina M.2ORCID,Difilippantonio Simone2ORCID,Biernat Wojciech3ORCID,Bieńkowski Michał3ORCID,Pęksa Rafał3ORCID,Duchnowska Renata4ORCID,Jassem Jacek5ORCID,Brastianos Priscilla K.6ORCID,Metellus Philippe7ORCID,Bialecki Emilie7ORCID,Woodroofe Carolyn C.8ORCID,Wu Haitao8ORCID,Swenson Rolf E.8ORCID,Steeg Patricia S.1ORCID

Affiliation:

1. 1Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.

2. 2Laboratory Animal Sciences Program, Frederick National Laboratory for Cancer Research (FNLCR), Frederick, Maryland.

3. 3Department of Pathology, Medical University of Gdańsk, Gdańsk, Poland.

4. 4Department of Oncology, Military Institute of Medicine, Warsaw, Poland.

5. 5Department of Oncology and Radiotherapy, Medical University of Gdańsk, Gdańsk, Poland.

6. 6Division of Neuro-Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts.

7. 7Ramsay Général de Santé, Hôpital Privé Clairval, Département de Neurochirurgie and Aix-Marseille Université, Institut de Neurophysiopathologie – UMR 7051, Marseille, France.

8. 8Chemistry and Synthesis Center, National Heart, Lung and Blood Institute, NIH, Bethesda, Maryland.

Abstract

Abstract Advances in drug treatments for brain metastases of breast cancer have improved progression-free survival but new, more efficacious strategies are needed. Most chemotherapeutic drugs infiltrate brain metastases by moving between brain capillary endothelial cells, paracellular distribution, resulting in heterogeneous distribution, lower than that of systemic metastases. Herein, we tested three well-known transcytotic pathways through brain capillary endothelial cells as potential avenues for drug access: transferrin receptor (TfR) peptide, low-density lipoprotein receptor 1 (LRP1) peptide, albumin. Each was far-red labeled, injected into two hematogenous models of brain metastases, circulated for two different times, and their uptake quantified in metastases and uninvolved (nonmetastatic) brain. Surprisingly, all three pathways demonstrated distinct distribution patterns in vivo. Two were suboptimal: TfR distributed to uninvolved brain but poorly in metastases, while LRP1 was poorly distributed. Albumin distributed to virtually all metastases in both model systems, significantly greater than in uninvolved brain (P < 0.0001). Further experiments revealed that albumin entered both macrometastases and micrometastases, the targets of treatment and prevention translational strategies. Albumin uptake into brain metastases was not correlated with the uptake of a paracellular probe (biocytin). We identified a novel mechanism of albumin endocytosis through the endothelia of brain metastases consistent with clathrin-independent endocytosis (CIE), involving the neonatal Fc receptor, galectin-3, and glycosphingolipids. Components of the CIE process were found on metastatic endothelial cells in human craniotomies. The data suggest a reconsideration of albumin as a translational mechanism for improved drug delivery to brain metastases and possibly other central nervous system (CNS) cancers. In conclusion, drug therapy for brain metastasis needs improvement. We surveyed three transcytotic pathways as potential delivery systems in brain-tropic models and found that albumin has optimal properties. Albumin used a novel endocytic mechanism.

Funder

National Institutes of Health

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3